Lb Pharmaceuticals (LBRX) Non Operating Income (2024 - 2026)

Lb Pharmaceuticals' Non Operating Income history runs 3 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 171.59% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $8.3 million (changed N/A YoY), while the FY2025 annual figure was $5.2 million, up 200.75% from the prior year.
• Non Operating Income for Q1 2026 stood at $3.0 million, up from $2.4 million in the prior quarter.
• The five-year high for Non Operating Income was $3.0 million in Q1 2026, with the low at $469000.0 in Q4 2024.
• The 3-year median for Non Operating Income is $1.8 million (2024), against an average of $1.8 million.
• Peak annual rise in Non Operating Income reached 411.51% in 2025, while the deepest fall reached 11.15% in 2025.
• Lb Pharmaceuticals' Non Operating Income stood at $469000.0 in 2024, then jumped by 411.51% to $2.4 million in 2025, then rose by 27.14% to $3.0 million in 2026.
• Business Quant data shows LBRX's Non Operating Income at $3.0 million in Q1 2026, $2.4 million in Q4 2025, and $1.7 million in Q3 2025.